The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study (CLASP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03170349 |
|
Recruitment Status :
Active, not recruiting
First Posted : May 31, 2017
Last Update Posted : October 1, 2020
|
Sponsor:
Edwards Lifesciences
Information provided by (Responsible Party):
Edwards Lifesciences
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to assess the safety, performance and clinical outcomes of the Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Mitral Valve Regurgitation | Device: Mitral Valve Repair | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 124 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study |
| Actual Study Start Date : | June 27, 2017 |
| Actual Primary Completion Date : | July 30, 2020 |
| Estimated Study Completion Date : | August 2025 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Edwards PASCAL Transcatheter Mitral Valve Repair System |
Device: Mitral Valve Repair
Minimal Invasive Transcatheter Mitral Valve Repair |
Primary Outcome Measures :
- Composite of major adverse events (MAE) defined as cardiovascular mortality, stroke, myocardial infarction, new need for renal replacement therapy, severe bleeding and re-intervention for study device related complications at 30 days. [ Time Frame: The primary endpoint will be assessed at 30 days. ]
Secondary Outcome Measures :
- Mitral regurgitation reduction [ Time Frame: 30 days, 6 months, 1 year ]
- All-cause mortality [ Time Frame: 30 days , 6 months, 1 year ]
- Recurrent heart failure hospitalization [ Time Frame: 30 days , 6 months, 1 year ]
- Change in Six Minute Walk Test (6MWT) distance [ Time Frame: 6 months and 1 year ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Signed and dated IRB/ethics committee approved study consent form prior to study related procedures
- Eighteen (18) years of age or older
- New York Heart Association (NYHA) Functional Class II-IVa heart failure despite optimal medical therapy
- Candidacy for surgical mitral valve repair or replacement determined by Heart Team evaluation
- Clinically significant mitral regurgitation (moderate-to-severe or severe mitral regurgitation) confirmed by transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE).
- The primary regurgitant jet is non-commissural. If a secondary jet exists, it must be considered clinically insignificant.
- Mitral valve area (MVA) ≥ 4.0 cm² as measured by planimetry. If MVA by planimetry is not measurable, pressure half-time measurement is acceptable.
Exclusion Criteria:
- Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
- Leaflet anatomy which may preclude PASCAL device implantation, proper device positioning on the leaflets, or sufficient reduction in mitral regurgitation.
- Mitral valve area (MVA) < 4.0 cm² as measured by planimetry (If MVA by planimetry is not measurable, PHT measurement is acceptable)
- Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
- Physical evidence of right sided congestive heart failure and echocardiographic evidence of severe right ventricular dysfunction
- Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
- Patient is currently participating or has participated in another investigational drug or device clinical study where the primary study endpoint was not reached at time of enrollment
- Patient is under guardianship
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03170349
Locations
Show 17 study locations
Sponsors and Collaborators
Edwards Lifesciences
Investigators
| Principal Investigator: | Gideon Cohen, MD | Sunnybrook Hospital | |
| Principal Investigator: | Ulrich Schafer, MD | University Medical Center Hamburg | |
| Principal Investigator: | Molly Szerlip, MD | The Heart Hospital Baylor |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Edwards Lifesciences |
| ClinicalTrials.gov Identifier: | NCT03170349 |
| Other Study ID Numbers: |
2016-05 |
| First Posted: | May 31, 2017 Key Record Dates |
| Last Update Posted: | October 1, 2020 |
| Last Verified: | September 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Device Product Not Approved or Cleared by U.S. FDA: | Yes |
| Product Manufactured in and Exported from the U.S.: | Yes |
Additional relevant MeSH terms:
|
Mitral Valve Insufficiency Heart Valve Diseases Heart Diseases Cardiovascular Diseases |